Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1

Status

Recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 3Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 2Esophageal Squamous Cell Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 281Specimen Handling 271pembrolizumab 253Cyclophosphamide 235Radiotherapy 227Nivolumab 184Cisplatin 172Biopsy 161Carboplatin 155Radiosurgery 143fludarabine 131Blood Specimen Collection 129Surveys and Questionnaires 120Gemcitabine 119Paclitaxel 116venetoclax 114Standard of Care 112Dexamethasone 107Bevacizumab 93Radiation 92Rituximab 91Oxaliplatin 89Cytarabine 88Ipilimumab 84Drug Therapy 84Capecitabine 84Doxorubicin 81durvalumab 80fludarabine phosphate 73Fluorouracil 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × nimotuzumab × 90 days × Clear all
NCT07601737 2026-05-22

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
182 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07535567 2026-04-30

NimoBenSeq

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Phase 2/3 Not yet recruiting
386 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07445048 2026-04-17

Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Phase 3 Recruiting
370 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07457528 2026-03-11

Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Recruiting
46 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡